YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCI...( ------------------------------------...)

Date:5/14/2009

------------------------------------------------------------------------- 4,501,499 6,645,952 Deferred revenue 3,522,556 4,414,256 Shareholders' equity: Share capital 172,921,153 172,921,153 Share purchase warrants - 3,150,539 Contributed surplus 12,848,942 9,123,824 Deficit (142,987,921) (133,182,485) ------------------------------------------------------------------------- 42,782,174 52,013,031 Basis of presentation Commitments ------------------------------------------------------------------------- $ 50,806,229 $ 63,073,239 ------------------------------------------------------------------------- ------------------------------------------------------------------------- YM BIOSCIENCES INC. Interim Consolidated Statements of Operations and Comprehensive Income (Expressed in Canadian dollars) ------------------------------------------------------------------------- Three months ended Nine months ended March 31, March 31, 2009 2008 2009 2008 ------------------------------------------------------------------------- (Unaudited) (Unaudited) Out-licensing revenue $ 776,127 $ 1,155,835 $ 3,823,296 $ 3,438,601 Interest income 201,635 622,029 1,009,323 2,039,663 ------------------------------------------------------------------------- 977,762
'/>"/>

SOURCE YM BioSciences Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
2. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
3. MichBio Leader Cites New Senate Biosciences Task Force and House Subcommittee as Evidence of States Growing Awareness of Industrys Economic Importance
4. Neurocrine Biosciences Reports First Quarter 2009 Results
5. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
6. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
7. ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs
8. LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
9. Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences
10. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
11. Cell Biosciences Launches Next-Generation Protein Characterization System